Saiju Jacob

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7199049/publications.pdf Version: 2024-02-01



SAULI LACOR

#	Article	IF	CITATIONS
1	A retrospective longitudinal cohort study of the clinical burden in myasthenia gravis. BMC Neurology, 2022, 22, 172.	1.8	11
2	CASPR2 antibody-related movement disorders: case series. Journal of Neurology, 2021, 268, 1533-1535.	3.6	4
3	Quantitative Assessment of Response to Longâ€Term Treatment with Intravenous Immunoglobulin in Patients with Stiff Person Syndrome. Movement Disorders Clinical Practice, 2021, 8, 868-874.	1.5	7
4	The Role of Plasma Exchange in the Treatment of Refractory Autoimmune Neurological Diseases: a Narrative Review. Journal of NeuroImmune Pharmacology, 2021, 16, 806-817.	4.1	13
5	Age at onset predicts outcome in aquaporin-4-IgG positive neuromyelitis optica spectrum disorder from a United Kingdom population. Journal of the Neurological Sciences, 2021, 431, 120039.	0.6	5
6	Response to eculizumab in patients with myasthenia gravis recently treated with chronic IVIg: a subgroup analysis of REGAIN and its open-label extension study. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642091178.	3.5	16
7	â€~Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab. Journal of Neurology, 2020, 267, 1991-2001.	3.6	30
8	Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. Journal of the Neurological Sciences, 2020, 412, 116803.	0.6	110
9	Human hippocampal CA3 damage disrupts both recent and remote episodic memories. ELife, 2020, 9, .	6.0	37
10	Healthcare resource utilization by patients with treatment-refractory myasthenia gravis in England. Journal of Medical Economics, 2019, 22, 691-697.	2.1	7
11	False-positive acetylcholine receptor antibody results in patients without myasthenia gravis. Journal of Neuroimmunology, 2019, 332, 69-72.	2.3	14
12	Longâ€ŧerm safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle and Nerve, 2019, 60, 14-24.	2.2	162
13	Glutamate Receptor Antibodies in Autoimmune Central Nervous System Disease: Basic Mechanisms, Clinical Features, and Antibody Detection. Methods in Molecular Biology, 2019, 1941, 225-255.	0.9	4
14	Slowly progressive distal muscle weakness: neuropathy or myopathy?. BMJ Case Reports, 2019, 12, .	0.5	0
15	Primary angiitis of the central nervous system (PACNS) – a rare and serious, but treatable entity. Neurology India, 2019, 67, 942.	0.4	1
16	Restless leg syndrome in patients with liver cirrhosis: Waiting for the shoe to drop. Neurology India, 2019, 67, 657.	0.4	1
17	Distinct HLA associations of LGI1 and CASPR2-antibody diseases. Brain, 2018, 141, 2263-2271.	7.6	100
18	Focal CA3 hippocampal subfield atrophy following LGI1 VGKC-complex antibody limbic encephalitis. Brain, 2017, 140, 1212-1219.	7.6	89

Saiju Jacob

#	Article	IF	CITATIONS
19	Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurology, The, 2017, 16, 976-986.	10.2	472
20	A NEW CLINICAL TOOL (BRIT) TO MONITOR IVIG EFFICACY IN PATIENTS WITH STIFF PERSON SYNDROME. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, e4.38-e4.	1.9	1
21	CLINICAL FEATURES AND TREATMENT RESPONSE IN A LARGE UK COHORT OF STIFF PERSON SYNDROME PATIENTS. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, e4.39-e4.	1.9	1
22	A PROSPECTIVE CLINICAL AND IMMUNOLOGICAL STUDY OF LATE ONSET MYASTHENIA GRAVIS. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, e4.49-e4.	1.9	0
23	Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK. Multiple Sclerosis Journal, 2014, 20, 1533-1540.	3.0	107
24	RETROGRADE AMNESIA FOLLOWING AUTOIMMUNE LIMBIC ENCEPHALITIS. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, e4.79-e4.	1.9	0
25	Immunomodulation in Inflammatory Neuropathies: Rationale and Safety. Current Drug Safety, 2013, 8, 225-235.	0.6	4